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Review

Role of NADþ in regulating cellular and
metabolic signaling pathways
Sara Amjad 1, 11, Sabah Nisar 2, 11, Ajaz A. Bhat 2, Ab Rauf Shah 3, Michael P. Frenneaux 4, Khalid Fakhro 5, 6,
Mohammad Haris 2, 7, Ravinder Reddy 8, Zoltan Patay 9, Joseph Baur 10, Puneet Bagga 9, *
ABSTRACT
Background: Nicotinamide adenine dinucleotide (NADþ), a critical coenzyme present in every living cell, is involved in a myriad of metabolic
processes associated with cellular bioenergetics. For this reason, NADþ is often studied in the context of aging, cancer, and neurodegenerative
and metabolic disorders.
Scope of review: Cellular NADþ depletion is associated with compromised adaptive cellular stress responses, impaired neuronal plasticity,
impaired DNA repair, and cellular senescence. Increasing evidence has shown the efﬁcacy of boosting NADþ levels using NADþ precursors in
various diseases. This review provides a comprehensive understanding into the role of NADþ in aging and other pathologies and discusses
potential therapeutic targets.
Major conclusions: An alteration in the NADþ/NADH ratio or the NADþ pool size can lead to derailment of the biological system and contribute to
various neurodegenerative disorders, aging, and tumorigenesis. Due to the varied distribution of NADþ/NADH in different locations within cells,
the direct role of impaired NADþ-dependent processes in humans remains unestablished. In this regard, longitudinal studies are needed to
quantify NADþ and its related metabolites. Future research should focus on measuring the ﬂuxes through pathways associated with NADþ
synthesis and degradation.
Ó 2021 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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1. INTRODUCTION
Since the discovery of nicotinamide adenine dinucleotide (NAD), researchers have progressively learned more about its roles in cellular
function. NADþ has emerged as a critical modulator of cell signaling
and survival pathways [1]. Cellular NAD exists in two forms, oxidized
(NADþ) and reduced (NADH) [2]. NADþ and another essential intracellular coenzyme ﬂavin adenine dinucleotide (FADþ) play essential
roles in cellular oxidation-reduction (redox) reactions and are
responsible for accepting high-energy electrons and carrying them to
the electron transport chain (ETC) to synthesize adenosine triphosphate
(ATP) [3]. Regulation and maintaining a proper balance of the NADþ/
NADH and FADH2/FAD ratio is critical for normal cell function and
viability [4]. NADþ acts as a cofactor for enzymes involved in cellular
energy metabolism and various metabolic pathways such as glycolysis, fatty acid oxidation, and the citric acid cycle [5]. Both NADþ and
NADH play important roles as coenzymes in redox reactions, and an

imbalance in their ratio can impair ﬂux through these pathways’ reactions, resulting in dysregulated cellular metabolism.
However, ATP generated via glycolytic reactions is critical for
NAD þ regeneration from NADH [6]. The crucial role of NADþ in
different biological functions such as aging, metabolism, mitochondrial
function, immunological pathways, oxidative stress, gene expression,
and apoptosis has been extensively investigated [7]. Many studies
have found that altered NADþ levels play an important role in metabolic
disorders, neurodegenerative disorders, and tumorigenesis [8,9]. In
this review, we discuss the importance of cellular NADþ in aging,
neurodegeneration, metabolic disorders, and cancer.
2. NADþ BIOSYNTHESIS PATHWAYS
The intracellular concentration of NADþ is a balance between NADþ
consumption and synthesis. The biosynthetic pathways of NADþ play
an important role in maintaining NADþ pools, which are not only
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required for fueling redox metabolism but also to support NADþdependent signaling pathways. As NADþ-dependent signaling pathways involve the degradation of NADþ, cells require continuous
replenishment of NADþ that can be accomplished by an efﬁcient NADþ
biosynthesis [10]. The three canonical pathways for the synthesis of
NADþ in mammalian cells are the Preiss-Handler pathway, de novo
biosynthesis pathway, and NADþ salvage pathway (Figure 1) [11,12].
The formation of nicotinamide (NAM) or nicotinic acid (NA) adenine
dinucleotides from the corresponding mononucleotides and ATP constitutes a critical step for NAD generation [13]. The three isoforms of
nicotinamide mononucleotide adenylyl transferase (NMNAT1, 2, and 3)
that catalyze this reaction have different tissue and subcellular distributions [13]. NMNAT-1 is highly expressed in the skeletal muscle,
heart, kidney, liver, kidney, and pancreas [14,15]. In contrast, NMNAT2 is highly expressed in the brain and NMNAT-3 is highly expressed in
the erythrocytes, lungs, and spleen [16e18]. NMNAT-3 and in some
reports a minority of nicotinamide phosphoribosyltransferase (NAMPT)
[19], which lies upstream of NMNAT-3, were found to be mitochondrial, yet their localization status remains controversial. In contrast, all
of the other enzymatic activities associated with NADþ biosynthesis
occur in the cytosol and/or nucleus [20]. To identify the factors that
contribute to the reduction of NADþ levels associated with aging and
its related pathologies, including cancer, it is important to review the
NADþ biosynthesis pathways.
2.1. Preiss-Handler pathway
NA, which can be obtained from foods such as meat, redﬁsh, and nuts
and is also produced by the microbiome, is converted into NADþ through
the Preiss-Handler pathway. In this pathway, NA mononucleotide

(NAMN) forms from the reaction of NA with phosphoribosyl pyrophosphate (PRPP), a pentose phosphate that is catalyzed by NA phosphoribosyltransferase (NAPRT) [21]. NMNATs then convert NAMN into NA
adenine dinucleotide (NAAD), and then NAAD is converted into NADþ by
glutamine-dependent NAD synthase.
2.2. De novo biosynthesis pathway
This is the longest of the NADþ synthesis pathways and is active
mainly in the liver and kidneys. The amino acid tryptophan (Trp) is
catabolized through the kynurenine (KYN) pathway (comprising 9
steps) to generate quinolinic acid (QA) [22]. In the ﬁrst rate-limiting
step, Trp is oxidized to form N-formylkynurenine (NFK) by either
indoleamine-2,3-dioxygenase (IDO) or tryptophan-2,3-dioxygenase
(TDO) [23]. NFK then transforms into KYN, which results in either 3hydroxykynurenine or anthranilic acid forming 3-hydroxyanthranilic
acid (3-HAA), which is ﬁnally converted into unstable a-amino-bcarboxymuconate-ε-semialdehyde (ACMS). The spontaneous cyclization of ACMS forms QA. The second rate-limiting step is the formation
of NAMN from QA, which is catalyzed by quinolinate phosphoribosyltransferase. NAMN is then converted into NADþ through the PreissHandler pathway [24,25]. However, ACMS may exit the NADþ formation pathway if decarboxylated by ACMS decarboxylase, and inhibitors of this enzyme enhance NADþ synthesis [26]. QA generated by
these steps is then converted into NADþ, and conditions that lead to
the accumulation of QA can cause neurotoxicity [2].
2.3. Salvage pathway
This is the major pathway for NADþ biosynthesis in most tissues in
mammals. Enzymatic activities of NAD-consuming enzymes produce

Figure 1: Representation of NADD biosynthesis pathways. Biosynthesis pathways and cellular metabolism of NADþ. NAD precursors such as NR, NA, NAM, and Trp provided
by diet can be converted into NAD via three pathways. In the Preiss-Handler pathway, NA is converted into NAMN by NAPRT, NAMN is converted into NAAD by NAD by NMNATs,
and NAAD is converted into NAD by NADSYN. In the de novo synthesis pathway, Trp is converted into QA in a series of steps, which is then converted into NAD by forming NAMN
and NAAD. In contrast, in the salvage pathway, NR and NAM provided by diet are converted into NAD by forming NMN by enzymes NAMPT and NRK [2]. The equilibrium in each
subcellular compartment such as the nucleus and mitochondria is determined by NAD/NADH redox ratios. ETC is a signiﬁcant contributor to the conversion of NADH into NAD.
Additionally, NAD-consuming enzymes such as PARPs and sirtuins catalyze NAM production in subcellular compartments, which can be used for NAD synthesis via the salvage
pathway.
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NAM as a by-product. NAM can also be obtained from the diet. In the
salvage pathway, the formation of nicotinamide mononucleotide (NMN)
from NAM is catalyzed by NAMPT. NAM can also be methylated by
nicotinamide N-methyltransferase (NNMT) to form 1-methyl-nicotinamide, which is further metabolized and excreted [27]. NMN also
forms by phosphorylation of nicotinamide riboside (NR) by nicotinamide
riboside kinase 1e2 (NRK 1e2) and then converted into NADþ by
NMNATs [2]. The cellular level of NADþ can be increased either by
stimulation or activation of enzymes involved in NADþ biosynthesis
such as NADþ precursors NMN, NR, and NAM [12] or by inhibition of
enzymes that consume or degrade NADþ such as CD38, poly-ADPribose-polymerases (PARPs), and sterile alpha and toll-interleukin receptor-containing motif (SARM1) [11]. Flavonoids such as luteolin,
luteolinidin, apigenin, quercetin, and kuromanin and a highly potent
thiazoloquin(az)olin(on)e 78c are reported to be effective CD38 inhibitors that can boost NADþ levels and have beneﬁcial effects in
various human diseases [28e31]. PARP inhibitors such as olaparib,
niraparib, rucaparib, talazoparib, veliparib, and PJ34 play important
roles in preserving and/or boosting NADþ levels in different pathologies
[32e38].
3. ROLES OF NADþ AND SIRTUINS IN CELLULAR
MAINTENANCE
Reduced levels of NADþ coupled with a shift toward NADH are
considered a hallmark of aging, although the underlying causes remain
unclear [39]. Preclinical studies in aging models show that increasing
NADþ levels reduces age-related immune and metabolic changes and
could potentially be used as a therapeutic strategy for treating agingassociated pathologies [12,40e42]. The role of NADþ in various diseases has been evaluated using genetically modiﬁed mice or by

boosting or replenishing NADþ levels by administering precursors of
NADþ biosynthesis [43,44]. One crucial role of NADþ in cellular
maintenance is related to sirtuins. Sirtuins are NADþ-dependent
deacylases and ADP ribosyltransferases that consume NADþ and are
crucial to maintaining and regulating cellular homeostasis. They may
be affected by age-dependent declines in NADþ levels [41,45]. The
loss of sirtuins can lead to mitochondrial dysfunction, which can cause
redox imbalance, leading to damaged cell proteins, lipids, and DNA.
Damage to DNA can cause chromosomal aberrations and gene mutations, leading to the development of several chronic diseases,
including cancer [46]. Reduced levels of sirtuins also lead to agerelated diseases, as members of the sirtuin family such as sirtuin 1
(SIRT1) delay aging processes by catalyzing histone deacetylation and
regulating transcription factors [47]. Nutritional and environmental
factors signiﬁcantly affect intracellular NADþ levels. Declining levels of
cellular NADþ can impair sirtuin activities and alter the epigenetic
chromatin structure [48] and mitochondrial metabolism, leading to
increased oxidative stress and decreased ATP production. This increase in oxidative stress promotes inﬂammation, aggravating cellular
injury [49] (Figure 2). Aging is characterized by a continued shift in
metabolic activity, which increases from childhood to adulthood and
declines afterward [50]. Although age-related metabolic activity
changes correlate with cellular NADþ levels [51], the exact mechanisms underlying decreased NADþ levels remain unclear [39]. The
expression and activity of NADase CD38 have also been associated
with an age-related decline in NADþ and may serve as potential
therapeutic targets for age-related diseases [51]. Researchers are
focusing on unraveling the molecular mechanisms involved in the
physiological decline of NADþ levels. Measuring changes in NADþ
levels in vivo may provide information about the altered redox potential
associated with age-related diseases and can subsequently be linked

Figure 2: Role of NAD in aging, neurodegeneration, and cancer. DNA damage caused by stress or aging activates PARP. PARP activation leads to reduced levels of cytosolic
NAD and mitochondrial dysfunction, which contribute to aging and neurodegeneration. Any disturbance in levels of NADþ/NADH (redox homeostasis) can upregulate oncogenic
signaling pathways, leading to tumorigenesis.
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with altered cellular metabolism (Figure 2). The decline in NADþ with
aging and in progeroid states (as reported in Werner and Cockayne
syndromes) [52,53] can result in the development of various metabolic
abnormalities [51]. As nuclear NAD þ -dependent enzymes regulate
mitochondrial function, it is suggested that an impairment in the
oxidative phosphorylation (OXPHOS) mechanism during aging might be
accelerated by the depletion of nuclear NADþ [54]. Thus, to understand
the molecular mechanisms underlying the aging process, it is crucial to
study the effects of decreased cellular NADþ levels and understand
how different factors such as oxidative stress, inﬂammation, and DNA
damage impact the cellular metabolism of NADþ during aging. Many
studies show a relationship between age-related illness, its comorbidities, and metabolic changes.
4. NADþ IN AGING
The systemic decline in NADþ has been associated with many hallmarks of aging. In addition to age-related mitochondrial content
changes such as a change in the volume, integrity, and functionality of
mitochondrial DNA due to increased ROS accumulation, other mechanisms also contribute to age-related declines in NADþ [39,55]. The
most recognized mechanisms include an increase in NADþ-consuming
enzymes such as poly-ADP-ribose-polymerase 1 (PARP1) and SIRT1
[56,57] due to inﬂammation or DNA damage. PARP1 activation allows
the recruitment of DNA repair proteins to repair damaged DNA.
Although PARP1 activation is crucial for genomic maintenance,
hyperactivation of PARP1 can cause a reduction in NADþ levels [58].
NADþ reduction leads to reduced SIRT1 activity, increasing
proliferator-activated receptor gamma coactivator 1-alpha (PGC)-1a
acetylation and decreasing transcriptional factor A mitochondria
(TFAM) levels [59]. This decline in NADþ levels can lead to cellular
dysfunction and DNA damage and aggravate age-related pathologies.
Changes in the mitochondrial content of cells with age can also
compromise mitochondrial function and contribute to age-related
NADþ decline (Figure 3). Possible explanations for the age-related
decline in NADþ levels include increased expression of CD38 protein, dysregulation of circadian rhythms that reduce the expression of

NAMPT, and high levels of PARP activity due to DNA damage,
inﬂammation, or metabolic stress [60e62]. Studies show that blocking
PARP activity can help recover NADþ levels and mitochondrial function
[54,62]. Pharmacological inhibition or deletion of the PARP1 gene
enhances mitochondrial content and oxidative metabolism in mice
[33,63].
Supplementation of NADþ precursor (NR) increases NADþ levels,
enhances oxidative metabolism, and protects against metabolic abnormalities, which SIRT1 and SIRT3 [64] may in part mediate. NR
treatment enhances SIRT1 activity and leads to a higher SOD2
expression, which results in the deacetylation and activation of FOXO1
[64]. NR treatment was also found to deacetylate PGC-1a in the
muscle, liver, and brown adipose tissue, stimulate sirtuin activity, and
enhance mitochondrial gene expression in NR-fed mice [64]. Another
study found that treatment with NR rejuvenate muscle stem cells and
delays senescence in neural and melanocyte stem cells in aged mice,
thus increasing the mouse life span [41]. Cellular senescence associated with tissue decline alters adult stem cell functioning such as
intestinal stem cells (ISCs) during aging. Supplementation of NR rejuvenates ISCs in aged mice and helps rescue repair defects in the
aging gut [65].
NMN administration effectively mitigates age-associated physiological
decline by suppressing age-associated weight gain and gene
expression changes, enhancing energy and mitochondrial oxidative
metabolism and improving insulin sensitivity and plasma lipid proﬁles
in chow-fed wild-type C57BL/6N mice [40]. Studies in aging models
show that NMN administration enhances energy metabolism and
mitochondrial oxidative metabolism [40,66]. Interestingly, a study
showed that NADþ repletion restores microvasculature and capillaries’
number and density in old mice [67]. Dietary treatment with NR has
also been shown to improve cognitive function and synaptic plasticity in
Alzheimer’s disease (AD) by promoting the degradation of b-secretase
through PGC-1a [68]. Augmentation of NADþ levels by supplementing
NR also improves cardiovascular and other physiological functions
associated with aging, and NR is well tolerated in middle- and olderaged individuals [69]. Increasing intracellular NADþ levels by administering NR/NMN delays memory loss, normalizes neuromuscular

Figure 3: NADþ depletion with increasing age is caused by several factors such as inefﬁcient metabolism or protein consumption, increased activity of NADþ-consuming enzymes
CD38/PARP, mitochondrial dysfunction, DNA damage, cellular dysfunction, and NAMPT depletion. NADþ can be restored by manipulating enzymes in NADþ synthesis pathways.
The NADþ concentration can be replenished by increasing the activity of NAMPT, niacin, NMN, and NR. Moreover, in many cases, inhibition of PARP/CD38 also helps restore NADþ.
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function, and extends life spans in ataxia-telangiectasia-deﬁcient mice
[70]. In some DNA repair disorders, the neurological phenotype is due
to mitochondrial alterations such as in xeroderma pigmentosum [71].
Mitochondrial alterations are a consequence of reduced NADþ levels
due to the hyperactivation of PARP1, and these mitochondrial abnormalities can be rescued by inhibiting PARP1 or supplementation with
NADþ precursors [71]. Augmentation of NADþ levels by administering
NR rescues the mitochondrial phenotype in Xpa//Csa/ (CX) mice
[71]. Aging is also associated with decreased levels of retinal NADþ,
leading to eye conditions such as glaucoma that can damage the optic
nerve. Oral administration of NA, an NADþ precursor, protects mice
against glaucoma development by rendering retinal ganglion cells
more resistant to intraocular pressure [72]. All of these studies show
that NADþ and its associated metabolites are implicated in aging and
its related pathologies.
5. ROLE OF NADþ IN NEURODEGENERATIVE DISORDERS
Mitochondrial dysfunction in neurons is a signiﬁcant contributor to agerelated neurodegenerative disorders such as AD and Parkinson’s
disease (PD) [73]. Aging contributes to the progression of neurodegenerative disorders, as it accelerates the production and accumulation of reactive oxygen species (ROS), triggering various cellular
processes that contribute to DNA damage and impairment in mitochondrial functioning [74]. Several studies have documented NAD þ and NAD-dependent sirtuins’ neuroprotective role in many neurodegenerative disorders [75,76]. Being the only de novo NADþ synthesis
pathway in mammals, the KYN pathway modulates neuronal functions
and acts as a double-edged sword as it generates both neuroprotective
metabolites and neurotoxic intermediates [77] (Figure 4). The maintenance of KYN pathway metabolites is determined by enzymes

localized in the astrocytes and microglia in the brain, and any ﬂuctuations in levels of these metabolites can impair neurotransmitter
systems, which can lead to various neurological disorders [78]. For
NADþ depletion associated with aging-related neurodegenerative
disorders, various NADþ augmentation strategies such as supplementation/treatment with NADþ precursors, PARP inhibitors (PARPi),
or sirtuin activators can help restore mitochondrial function and
enhance neuronal function, which can improve cognitive function [77].
Preclinical studies suggest that PARP1 inhibition helps treat AD, PD,
and Huntington’s disease (HD) [79,80]. Axonal degeneration is a
hallmark of many neurological diseases, including neurodegenerative
disorders, and delaying axonal degeneration can increase survival and
decrease disease progression [81]. Activation of SARM1 is found to
promote axonal degeneration by initiating a local destruction program
that depletes NADþ [82]. In contrast, the overexpression of NMNAT1 is
found to inhibit axonal degradation by blocking SARM1-mediated
NADþ depletion [83]. Interestingly, elevated levels of NADþ in CD38and PARP1-deﬁcient mice are found to have no effect on axonal
degeneration and do not provide axonal protection, suggesting that the
loss or deletion of these NADþ-consuming enzymes has no effect on
NMNAT1-mediated axonal protection [81].
5.1. Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive disorder characterized by
impaired cognition and memory processes caused by neuronal
degeneration. AD is the most common form of dementia. It worsens
over time and affects the brain regions responsible for learning and
emotional control, leading to cognitive decline [84]. The seminal role of
b-amyloid (Ab) protein has been assessed in many AD studies [85,86].
Amyloid plaques resulting from the accumulation of Ab proteins in the
nerve cells set off a cascade of events that impair neurotransmission,

Figure 4: Altered NAD metabolism is associated with neurodegeneration. Axonal injury leads to the activation of SARM1, which reduces NAD þ levels and leads to axonal
degeneration. The overexpression of NMNAT1 inhibits SARM1 and protects injured axons. NAD levels are associated with axonal degradation, and impairment in the KYN pathway
causes ﬂuctuations in KYN pathway metabolite levels, which impairs the neurotransmission process and leads to neurodegeneration and the development of neurological disorders
[201].
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leading to synaptic loss, which is the major cause of cognitive decline
in AD patients [87]. Increased expression of NADþ is associated with a
decrease in the toxicity of Ab oligomers in AD [88]. Treatment with the
NADþ precursor NMN improves cognitive function in Ab oligomer AD
model rats and attenuates neuronal cell death in organotypic hippocampal slices treated in Ab oligomer culture media [88]. Supplementation with NMN in AD transgenic mice also attenuates
mitochondrial respiratory deﬁcits, Ab production, and synaptic loss,
and partially inhibits the activation of the JNK pathway and therefore
might be a therapeutic option for AD [89,90]. Furthermore, preclinical
studies show that treatment with NR reduces the formation of amyloid
plaques, improves contextual memory and cognitive function, and
attenuates synaptic plasticity by promoting PGC-1a-mediated b-secretase degradation, which prevents the production of Ab in the brain of
transgenic AD mouse models [68,91]. Supplementation with NR improves cognitive function, reverses DNA damage, and restores synaptic plasticity in the hippocampus of an AD mouse model (3  TgAD/
Polbþ/) with introduction of a DNA repair deﬁciency [84]. Several
studies have reported high cholesterol as a risk factor for developing
AD later in life, as elevated cholesterol levels can promote the production of Ab proteins [92]. Increased membrane cholesterol promotes
Ab-induced calpain activation, toxic 17 kDa tau production, and cell
death in mature neurons [93]. In contrast, decreased membrane
cholesterol reduces mature neurons’ susceptibility to these Abmediated cellular processes [93]. The deﬁciency of niacin in aging
populations is also associated with dementia, a characteristic of AD.
Niacin may offer protection in AD by decreasing serum and intracellular
cholesterol levels [94]. Niacin also serves as a pharmacological agonist
of GPR109A and has been reported to reduce the progression of
atherosclerosis through GPR109A activation on immune cells, thus
showing the potential of GPR109A in reducing inﬂammation [95].
Moreover, niacin is also produced by gut microbiota and its deﬁciency
can lead to intestinal inﬂammation and pellagra [96]. A study showed
that niacin supplementation was found to suppress colitis and colon
cancer through the activation of GPR109A [97]. Furthermore, it is
suggested that the induction of liver X receptors (LXR) might be
associated with cholesterol-induced amyloid deposition in AD [98] as
LXRs are key regulators of cholesterol and fatty acid metabolism.
Speciﬁcally, LXR agonists can facilitate Ab-42 clearance and inhibit the
amyloid precursor protein’s processing, thereby being a therapeutic
option for AD [99]. Treatment with niacin increases the mRNA
expression of LXRa and PPARg and promotes cholesterol efﬂux in
hypercholesterolemic rabbit adipocytes [100]. Several studies have
reported a decline in levels of NMNAT2 before neurodegeneration in
mouse models of dementia, Parkinsonism-17, and AD [101,102]. In
addition to its role in NADþ synthesis, NMNAT2 acts as a chaperone
and aids in the clearance or refolding of misfolded Tau aggregates, a
characteristic of AD, by forming a complex with heat shock protein 90
(HSP90), thereby reducing proteotoxic stress to maintain neuronal
health [103]. Deletion of NMNAT2 is found to increase the vulnerability
of cortical neurons to proteotoxic stress and excitotoxicity [103]. Oral
NAM has been found to selectively reduce phosphoThr231-tau and
restore cognition in an AD mouse model through a mechanism similar
to that of SIRT1 inhibition [102]. An ex vivo study showed that NAM
treatment reduced lipid peroxidation, ROS production, and protein
oxidation and improved mitochondrial reduction capacity against Ab
(1e42) in rat synaptosomes [104]. In contrast, a study demonstrated
that niacin-deﬁcient rats showed decreased NADþ and intracellular
cyclic ADP-ribose (cADPR) levels and improved spatial learning ability
[105]. However, niacin-supplemented rats showed increased NADþ
and cADPR levels and an impaired spatial learning ability in a Morris
6

water maze test [105]. The deletion of CD38, an NADþ glycohydrolase,
in an AD mouse model reduced Ab plaque load and improved spatial
learning, suggesting a role of CD38 inhibition in treating AD [106].
5.2. Parkinson’s disease
PD is a progressive neurodegenerative disorder characterized by both
motor (resting tremors, bradykinesia, and muscular rigidity) and nonmotor features due to the loss of striatal dopaminergic and nondopaminergic neurons [107,108]. The core pathological process in
PD is the loss of dopaminergic neurons in the substantia nigra, which
leads to the depletion of dopamine in the striatum region, and these
changes are associated with bradykinesia [109,110]. The NADþ/NADH
ratio and NAD/NADP ratio, also known as the niacin index, are
signiﬁcantly reduced in PD patients [111]. Supplementation of lowdose niacin was found to modulate the niacin index, GPR109A, and
improve motor and cognitive functions in a PD patient with no side
effects [112]. Niacin supplementation was also found to improve PD
symptoms such as rigidity and bradykinesia, but a high dose of niacin
resulted in side effects such as nightmares and skin rashes in a PD
patient [113]. A case study also reported supplementation with NADþ
improved cellular resilience to dopaminergic neuronal loss in a patient
with PD [114]. NAM plays both neuroprotective and neurotoxic roles in
PD [115]. Supplementation with NAM rescues mitochondrial defects in
Parkin and PINK1 models of PD [116,117]. A recent study by
Schӧndorf et al. reported that supplementation with NR restored
mitochondrial function in neurons obtained from stem cells of a patient
with PD and that NR prevented motor decline and loss of dopaminergic
neurons in ﬂy models of PD [118]. SIRT1 was downregulated in
postmortem tissue samples from patients with PD, and overexpression
of SIRT1 protected SH-SY5Y cells from toxin-induced cell death and
reduced the formation of a-synuclein aggregates [119].
5.3. Huntington’s disease
Huntington’s disease (HD) is a progressive autosomal-dominant
neurodegenerative disorder caused by the expansion of glutamine
repeats in huntingtin protein (HTT) [120]. HD is characterized by
cognitive decline, mood alterations, and repetitive involuntary choreiform movements caused by the degeneration of striatal spiny neurons
[77]. Oxidative stress and mitochondrial dysfunction are the main
cellular features of patients with HD. Neuroactive metabolites in the
KYN pathway generated by the degradation of tryptophan are implicated in the pathogenesis of neurodegenerative diseases, including HD
[121,122]. It is suggested that NR can enhance mitochondrial function
via the SIRT1 and SIRT3 PGC-1a pathway and could also delay the
translocation of mutant Htt into the nucleus, demonstrating that it is a
potential pharmacologic agent for treating HD [123]. A study also
showed that reduction in SIRT2 levels leads to increased survival of
photoreceptor neurons, thereby exhibiting a neuroprotective effect in
Httex1p Q93-expressing ﬂy models of HD [124]. However, brainspeciﬁc knockout of SIRT1 worsens brain pathology, whereas SIRT1
overexpression improves survival and expression of the brain-derived
neurotrophic factor in an HD mouse model [120]. As many studies
have reported the neuroprotective effect of PARP inhibition in HD
mouse models [80,125], the synergistic effect of PARPi with NR
treatment needs to be explored in HD.
6. ROLE OF NADþ IN METABOLIC DISORDERS
In the last few decades, the increasing prevalence of metabolic disorders has added to the urban population’s global health burden.
Metabolic disorders include a cluster of risk factors such as obesity,
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insulin resistance, hypertension, and dyslipidemia, leading to the
development of type 2 diabetes (T2D) and cardiovascular pathologies
[126]. Levels of endogenous metabolites reﬂect the nutrient status in
cells, and these levels determine the redox state and in turn are
inﬂuenced by the redox state of NADþ [127]. Levels of NADþ directly
inﬂuence metabolic enzymes’ activity in various energy-production
pathways and indirectly inﬂuence many more downstream of those
effects. Regulation of the intracellular NADþ pool seems to have a
therapeutic potential in treating metabolic syndrome and modulates
processes associated with the pathogenesis of obesity, non-alcoholic
fatty liver disease (NAFLD), and T2D [128].
6.1. Diabetes
Increased NADH levels cause reductive stress, elevating cellular ROS
levels and leading to insulin resistance, insulin deﬁciency, and cell
death [129]. Thus, restoring NADþ can help decrease the redox
imbalance in diabetes. Altered or defective SIRT1 signaling mediated
by NADþ is implicated in insulin resistance and T2D, as SIRT1 positively regulates insulin signaling on multiple levels [130]. In addition,
NAMPT has a crucial role in regulating insulin secretion in pancreatic b
cells as it functions as an intra- and extracellular NAD biosynthetic
enzyme [131]. A study showed that impaired glucose tolerance and
reduced insulin secretion in pancreatic b cells of NAMPT(þ/) heterozygous mice could be rescued by NMN administration [131]. This
study implicated that maintaining NADþ levels was important for
pancreatic functionality. NMN also efﬁciently restored NADþ levels by
ameliorating glucose intolerance in high-fat diet (HFD)-induced T2D
mice and further improved lipid proﬁles in age-induced T2D mice [43].
Another study demonstrated the neuroprotective effect of NR by
administering NR to prediabetic and T2D mice. NR signiﬁcantly
improved glucose tolerance, reduced weight gain, reduced hepatic
steatosis, and protected against sensory neuropathy in prediabetic
mice and diabetic neuropathy in T2D mice [132]. Although replenishing
NADþ using NAM-related compounds appears to be successful in
preclinical models, it should be noted that these compounds can also
lead to an increase in NAM catabolites, which may act as uremic
toxins, especially in patients with diabetes due to impaired NAM
salvage pathway reactions [133]. Polyphenols, benfotiamine, aldose
reductase inhibitors, acetyl-L-carnitine, or insulin sensitizers (in T2D)
are all worthy of consideration as combinatorial therapies with NAD
precursors to mitigate the effects of NAM catabolites [133]. A study
found that nicotinamide treatment increased blood glucose and plasma
N0 -methylnicotinamide concentrations in rats. Exposure to N0 -methylnicotinamide reduced NAD contents in the rat liver and muscle and
increased levels of H2O2 in the rat plasma, suggesting a potential role
of N0 -methylnicotinamide in T2D [134].
Moreover, the clearance of N0 -methylnicotinamide is found to be slow
in patients with diabetes [134]. Under hyperglycemic conditions,
glucose ﬂux into the glycolytic pathway, Krebs cycle, and polyol
pathway may increase, resulting in the overproduction of NADH, which
leads to an increase in ROS due to an overload in mitochondrial NADH,
thereby contributing to insulin resistance [129] (Figure 5). Inhibition of
mitochondrial electron transport chain complex I by rotenone,
amobarbital, and NDUFA13 knockdown helped improve glucose homeostasis independently of AMPK activation in diabetes [135].
Moreover, inhibition of complex I by rotenone resulted in increased
NADH levels and reduced cellular NADþ/NADH ratios, thus showing the
efﬁcacy of inhibiting complex I for the alleviation of hyperglycemia
[135]. In such cases, several anti-hyperglycemic drugs such as metformin, thiazolidinediones, berberine, and rotenone have shown
glucose-lowering effects with improved glucose tolerance and insulin

sensitivity [135]. A clinical study showed that there was no effect of NR
supplementation on insulin sensitivity and endogenous glucose production in obese insulin-resistant men [136].
6.2. Obesity
Obesity reduces enzymatic activities in the mitochondria, promotes
metabolic inﬂexibility, and is associated with T2D and cardiovascular
diseases. Obesity is associated with altered mitochondrial and NADþ
homeostasis in adipose tissues, resulting in the enlargement of adipose tissues, making them the most plastic organ in the body [137].
Adipocytes help regulate and maintain energy metabolism, thereby
preserving mitochondrial function. An excess in energy substrates can
lead to mitochondrial dysfunction, with alterations in lipid and glucose
metabolism, contributing to the development of metabolic disorders
[138]. Biosynthesis of NADþ in the adipose tissue depends on the
expression of NAMPT, and the expression of NAMPT is reduced in the
adipose tissue of obese patients [139]. Although the function and
physiological relevance of the extracellular form of NAMPT (eNAMPT)
remain controversial, a recent preclinical study observed that secretion
of eNAMPT is mediated by SIRT1-dependent deacetylation in adipocytes, which promotes the regulation of hypothalamic NADþ levels by
supplying NMN to the hypothalamus [140]. Another preclinical study
found that extracellular vesicle-contained eNAMPT promotes NADþ
biosynthesis, counteracts aging, and extends life span in aged mice
[141]. However, the absence of adipose NAMPT can cause adipose
tissue ﬁbrosis, alter adipose tissue plasticity, and reduce mitochondrial
respiratory capacity [142].
6.3. Hepatic steatosis and non-alcoholic fatty liver disease
Although NAMPT enhances the levels of NADþ in hepatocytes, they can
maintain a substantial level of NADþ in the absence of NAMPT through
the de novo synthesis pathway [143]. Primary hepatocytes can
maintain the mitochondrial NADþ pool independent of NAMPT, suggesting that mitochondrial NADþ is less affected by the absence of
NAMPT than by cytosolic or nuclear NADþ [143]. Supplementation with
NADþ precursors such as NR improves mitochondrial functions in the
liver and prevents hepatic lipid accumulation in high-fat diet-induced
obesity [64]. The overexpression of NNMT induces hepatic steatosis
and ﬁbrosis and decreases liver NADþ in mice fed a high-fat diet
containing NAM, thus contributing to fatty liver disease [27].
Members of the sirtuin family are associated with inﬂammation and
energy metabolism and play an important role in maintaining metabolic
homeostasis [144]. Activation of SIRT1 protects against metabolic
damage induced by a high-fat diet, along with improved glucose
tolerance and protection against hepatic steatosis [145]. Treatment
with resveratrol, a natural phenol, improves mitochondrial function and
aerobic capacity in mice by activating SIRT1 and PGC-1a, a regulator
of cellular energy metabolism [146]. Many preclinical and clinical
studies showed that most SIRT genes are expressed in the white
adipose tissue (WAT) [137]. The expression of SIRT1, SIRT2, SIRT3,
SIRT4, and SIRT6 is downregulated in the WAT of HFD-fed rodents
[147e149]. However, in contrast, preclinical studies showed that
calorie restriction or nutrient depletion upregulates SIRT1 and SIRT2,
whereas SIRT4 expression is downregulated in the WAT [150e153].
Furthermore, hepatic steatosis primarily develops due to NAFLD progression, which leads to increased ROS and mitochondrial dysfunction
due to ectopic lipid accumulation [154]. Reduced levels of NADþ in the
liver and NAMPT in the visceral adipose tissue are associated with the
degree of steatosis in NAFLD [139,155]. In addition, there is direct
evidence of the downregulation of SIRT1, SIRT3, SIRT5, and SIRT6 in
patients with NAFLD [156]. Moreover, telomere shortening or
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Figure 5: The polyol pathway becomes highly active during hyperglycemia, leading to the massive production of NADH [202,203]. Consumption of NADþ by PARPs results in NADþ
decline. During diabetes, accumulation of NADH and depletion of NADþ leads to an increase in redox imbalance, which causes oxidative stress, decreased SIRT activity, decreased
ATP production, and increased cell death.

dysfunction can repress sirtuin function and lead to liver ﬁbrosis;
however, intriguingly, supplementation of NMN, a precursor of NADþ,
helps improve mitochondrial function and rescue liver ﬁbrosis [157].
Several studies showed that overexpression of SIRT1 and NR helps
restore diet-induced hepatic steatosis and mitochondrial dysfunction
by elevating NADþ levels [64,158,159]. However, another study
demonstrated that NAM supplementation protects hepatocytes against
palmitate-induced cell death by activating autophagy [160]. This
suggests that SIRT1, NAM, and NADþ precursors may be potential
therapeutic options for treating NAFLD.

8

6.4. Kidney diseases
Several studies indicated that reduced levels of NADþ and sirtuins are
associated with a plethora of renal diseases, and augmentation or
replenishment of NADþ can help treat chronic kidney diseases [161].
NADþ supplementation has been found to attenuate mesangial hypertrophy induced by high glucose by activating SIRT1 and SIRT3,
which block pro-hypertrophic AKT signaling and enhance the activity of
anti-hypertrophic AMPK signaling in mesangial cells, thus preventing
the induction of mTOR-mediated protein synthesis [162]. As aged
kidneys have decayed NADþ metabolism and reduced levels of SIRT1,
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supplementation with NMN can efﬁciently restore NADþ levels and
protect aged mice against cisplatin-induced acute kidney injury (AKI)
[163]. Moreover, the occurrence of AKI mostly depends on the mitochondrial biogenesis regulator PGC-1a, which is a critical determinant
of renal recovery from ischemic injury [164]. Supplementation with
NAM can effectively increase NADþ levels and renal function in
postischemic mice [164]. A preclinical study showed that cotreatment
with cisplatin and b-lapachone signiﬁcantly increased intracellular
NADþ levels and attenuated cisplatin-induced AKI in mice due to the
activation of NAD(P)H:quinone oxidoreductase 1 (NQO1) by b-lapachone [165]. A clinical study demonstrated that oral administration of
NAM increased circulating NADþ metabolites associated with less AKI
[166].
7. NADþ IN CANCER
Cancer cells prefer aerobic glycolysis over OXPHOS, even in the
presence of sufﬁcient oxygen for energy metabolism [167] due to
increased glucose uptake and glycolytic ﬂux but reduced activity of the
pyruvate dehydrogenase enzyme, which results in reduced pyruvate to
acetyl CoA [168]. However, recent studies demonstrated that OXPHOS
is upregulated in certain cancers [169]. Enhanced glycolysis is characterized by increased nutrient uptake and increased protein, lipid, and
nucleic acid synthesis rates to support high rates of cancer cell proliferation (Figure 6). Elevated levels of NADþ augment the process of
anaerobic glycolysis through glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and lactate dehydrogenase (LDH) and contribute to
cancer cell proliferation [170].
NAMPT is overexpressed in many types of cancers [171]. Overexpression of NAMPT accompanied by increased levels of NADþ
promotes cancer cell survival by making cells resistant to anti-cancer

reagents. Expression proﬁles of NAMPT in nine different cancer types
are shown in Figure 7. The well-known oncogene c-MYC regulates the
expression of NAMPT and enhances the process of glycolysis and
lactate production, leading to Warburg effects [172,173]. Furthermore,
NAMPT-speciﬁc inhibitors reduce NADþ levels by inhibiting energy
metabolism pathways such as glycolysis, citric acid cycle, and
OXPHOS, contributing to the suppression of cancer cell proliferation.
Studies also reported the association of eNAMPT with the progression
of cancers such as leukemia, hepatocellular carcinoma, and melanoma [174e177] and in the promotion of cancer-related inﬂammation
and epithelial to mesenchymal transition [178]. NADþ also regulates
DNA repair mechanisms, stress responses, and gene expression by
serving as a substrate for enzymes such as sirtuin, PARP, and NAD
glycohydrolase [170]. An interesting study showed that restoring NADþ
pools with NR can prevent DNA damage and tumor formation induced
by unconventional prefoldin RPB5 interactor (URI) in hepatocellular
carcinoma [179]. Overall survival rates in high- and low-NAMPT
expression groups in nine cancer types are shown in Figure 8.
NAPRT, a key enzyme mediating NAD biosynthesis from nicotinic acid,
plays an important role in cancer cell metabolism. Studies reported
downregulation of the NAPRT gene in cancers such as glioblastoma
and neuroblastoma [180,181]. A recent study reported overexpression
of the NAPRT gene in a subset of common types of cancer such as
breast, prostate, liver, pancreatic, ovarian, and head and neck cancers,
where it promotes cancer cell metabolism and reduces the susceptibility to NAMPT inhibitors and DNA-damaging drugs [182]. A recent
study showed that NAPRT silencing reduces the NADþ pool in human
ovarian and pancreatic cancer cells and sensitizes cells to NAMPT
inhibitors [182]. Silencing of NAPRT in cancer cells reduces OXPHOS,
protein synthesis, and ATP levels due to a reduction in mitochondrial
NADH [182]. Thus, NAPRT could prove beneﬁcial to understanding the

Figure 6: NAD metabolism in cancer cells. Cancer cells rely on increased glycolysis rates for energy production and regenerate NADþ by converting accumulating pyruvate into
lactate to maintain glycolysis. Excess lactate accumulation in tumor cells increases the level of NADH relative to NAD and perturbs the NAD/NADH balance in cells [204]. In contrast,
SIRT1 acts as an inactivator of HIFa and prevents its nuclear translocation. SIRT6 acts as a corepressor of HIFa to prevent the transcriptional process, and mitochondrial-localized
SIRT3 suppresses ROS production.
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Figure 7: Expression proﬁles of NAMPT in nine cancer types and corresponding normal tissues per the TCGA-GTEx GEPIA2 dataset.

function of NADþ biosynthetic mechanisms in cancer and likely serve
as a potential therapeutic target. PARPs are major mediators of cellular
responses associated with DNA repair and genomic stability. Activation
of PARP in cells with DNA damage or external stressors leads to NAD
depletion, as PARP consumes large amounts of NADþ during DNA
repair processes [183]. PARPi is an effective therapeutic agent against
BRCA1- and BRCA2-associated cancers, as BRCA mutations lead to
DNA double-strand breaks that cannot be efﬁciently repaired, thus
leading to the death of cancer cells. The regulation of PARP1 activity
has a signiﬁcant impact on the metabolism of NADþ [184]. The
endogenous PARP1 inhibitor macroH2A1.1 decreases the consumption
of NADþ in differentiating cells and increases the availability of mitochondrial NADþ, thereby enabling increased OXPHOS [184]. However,
PARPi is only effective against certain cancers. The combination of
PARPi and b-lapachone, an NAD(P)H:quinone oxidoreductase 1 (NQO1)

bioactivatable drug, has synergistic anti-tumor activity and blocks
PARP-dependent DNA repair in NQO1-overexpressing cancers such as
non-small cell lung cancer, breast cancer, and pancreatic cancer,
causing tumor-selective apoptosis [185]. However, any disturbances in
levels of NADþ inﬂuence the suppression of tumor formation mediated
by sirtuins. NADþ and NAMPT are involved in the activation of SIRT1
[186]. NAMPT controls the activity of SIRT1 by regulating NADþ levels.
The overexpression of NAMPT increases survival in a SIRT1-dependent
manner, whereas inhibition of NAMPT contributes to premature
senescence [187]. SIRT1 with NAMPT is overexpressed in many
cancers such as colorectal cancer, prostate cancer, and gliomas
[188e190]. Moreover, mitochondrial NADþ is a cosubstrate for
mitochondrial-localized SIRT3, SIRT4, and SIRT5. The overexpression
of nicotinamide nucleotide transhydrogenase (NNT), a mitochondrial
enzyme involved in the generation of NADPH from NADH and found to
enhance anti-oxidant capacity, induces differentiation and reduces
clonogenicity of glioblastoma tumor-initiating cells [191], whereas a
reduction in NADþ facilitates metastasis of hepatocellular carcinoma
cells [192]. SIRT2 is overexpressed in several cancers such as gastric
cancer [193] and hepatocellular carcinoma [194]. SIRT2 enhances
NADPH production and promotes leukemia cell proliferation by
deacetylation and activation of glucose-6-phosphate dehydrogenase
[195]. Consumption of large amounts of intracellular NADþ by PARPs
reduces the availability of NADþ for sirtuins, which can lead to aberrant
deacetylation of tumor suppressor proteins such as p53 [196]. As p53
is essential for the effective regulation of different cellular processes
such as apoptosis, autophagy, and senescence, p53 mutations can
result in cancer cell growth by enabling cancer cell survival under
nutrient-limiting conditions [197]. Additionally, the expression of p53
depends on the concentration of NADþ.
8. FUTURE DIRECTIONS

Figure 8: Overall survival rates of patients in low- and high-NAMPT expression groups
in nine cancer types (GBM, LUAD, LAML, LIHC, READ, PAAD, LGG, THYM, and DLBC)
using the TCGA-GTEx GEPIA2 dataset.
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Modern sedentary lifestyles are major factors contributing to the
development of age-related neurodegenerative disorders. Exercise and
dietary measures (calorie restriction) may prevent or delay the development of age-related neurological disorders. Emerging evidence from
many preclinical and clinical studies has deepened our understanding
of the role of NADþ- and NADþ-dependent enzymes in aging, synaptic
plasticity, neurodegenerative disorders, and cancer. NADþ depletion is
accentuated in aging, and many neurodegenerative disorders such as
AD, PD, and the augmentation of NADþ have proven beneﬁcial in
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mitigating the pathological features in preclinical models of these
disorders. Although the supplementation of NADþ precursors is
beneﬁcial for augmenting the levels of NADþ, it can be limited due to
their variable cell permeability, stability, dosage, and side effects. For
instance, a study demonstrated the possible adverse effects of high
doses of NAM, a precursor of NADþ, and suggested that high doses of
NAM can cause genomic instability, reduce cellular methyl pools, and
cause insulin resistance through methylated NAM [198]. Moreover,
niacin, a NAD þ precursor, was associated with mild or moderate
ﬂushing in many clinical trial studies [199]. However, this was due to
its interaction with GPR109A rather than NADþ per se, and the severity
and frequency of the ﬂushing was found to decrease with continued
niacin treatment [199].
Many unanswered questions relating to NADþ need to be further
explored. First, the NADþ/NADH ratio of NADþ/NADH is complicated
due to its varied distribution in different locations within the cell, and
the direct role of impaired NADþ-dependent processes in humans
remains unestablished. In this regard, longitudinal studies are needed
to quantify NADþ and its related metabolites, including the quantiﬁcation of NADþ and related metabolites in different disease conditions.
Second, the application of NAMPT inhibitors as an anti-cancer agent in
humans remains challenging. Although inhibiting NAMPT has been
effective in cancer cells as it attenuates glycolysis and activates
autophagy processes, complete inhibition or depletion of NAMPT can
cause motor neuron degeneration, motor function deﬁcits, mitochondrial dysfunction, and defective synaptic function in mice [200].
Therefore, it is necessary to select patients who efﬁciently adapt to
NAMPT inhibitor therapy.
The synergistic effect of DNA-damaging reagents and NAMPT inhibitors might help induce apoptosis in cancer cells, as the DNA
damage process can consume large amounts of NADþ. Modulation
of NADþ levels must be considered with caution, as high levels of
NADþ enhance glycolysis, which promotes cancer cell proliferation
and survival, thereby making NADþ a potential contributing factor to
tumorigenesis. Therefore, an anti-cancer clinical strategy with individual patient proﬁling is necessary to identify high-efﬁcacy treatments. Thus, more preclinical studies are required to understand the
mechanisms of NADþ replenishment in aging and neurodegenerative
and cancer models to understand the contribution of NADþ to these
morbidities. To date, administering NADþ precursors is well-tolerated
in humans, but their safety remains undetermined. Therefore, more
clinical trials are required to assess the safety and efﬁcacy of NADþ
precursors in aging and various neurological and metabolic
disorders.
9. CONCLUSIONS
It has been established that an alteration in the NADþ/NADH ratio can
lead to derailment of the biological system and contribute to various
neurodegenerative disorders, aging, and tumorigenesis. DNA damage
can lead to PARP activation and cause reductions in NADþ pools due to
perturbations in NADþ biosynthesis or consumption of NADþ by
NADþ-consuming enzymes. Increasing evidence shows the feasibility
of using NADþ precursors and intermediates to boost the levels of
NADþ to limit aging and neurodegenerative processes. However, the
therapeutic potential of using NADþ precursors for cancer treatment
remains inconclusive. Therefore, to better characterize the dynamics of
NADþ homeostasis in different diseases, future research should focus
on measuring the ﬂuxes through pathways associated with NADþ
synthesis and degradation, as every tissue in the body has its NADþ
metabolome.
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ABBREVIATIONS
NR
NA
NAM
Trp
NAMN
NAPRT
NAAD
NMN
NMNAT
NADSYN
NRK
QA
NAMPT
PARP
OXPHOS
ETC
Trp
NMN
PRPP
NADH
PGC-1a
ATP
NADPH
ROS
GBM
LUAD
LAML
LIHC
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PAAD
LGG
THYM
DLBC
URI
KYN
QA
NFK
IDO
TDO
3-HAA
ACMS
TFAM
AD
ISCs
AKI
LXR
Ab
HD
HTT
MRS
T2D
NAFLD

nicotinamide riboside
nicotinic acid
nicotinamide
tryptophan
nicotinic acid mononucleotide
nicotinic acid phosphoribosyltransferase
nicotinic acid adenine dinucleotide
nicotinamide mononucleotide
nicotinamide mononucleotide adenylyl transferase
NAD synthase
nicotinamide riboside kinase
quinolinic acid
nicotinamide phosphoribosyltransferase
poly (ADP-ribose) polymerase
oxidative phosphorylation
electron transport chain
tryptophan
nicotinamide mononucleotide
phosphoribosyl pyrophosphate
nicotinamide adenine dinucleotide reduced form
proliferator-activated receptor-g coactivator 1
adenosine triphosphate
nicotinamide adenine dinucleotide phosphate hydrogen
reactive oxygen species
glioblastoma multiforme
lung adenocarcinoma
acute myeloid leukemia
liver hepatocellular carcinoma
rectum adenocarcinoma
pancreatic adenocarcinoma
lower grade glioma
thymoma
diffuse large B cell lymphoma
unconventional prefoldin RPB5 interactor
kynurenine
quinolinic acid
N-formylkynurenine
indoleamine-2,3-dioxygenase
tryptophan-2,3-dioxygenase
3-hydroxyanthranilic acid
a-amino-b-carboxymuconate-ε-semialdehyde
transcriptional factor A, mitochondria
Alzheimer’s disease
intestinal stem cells
acute kidney injury
liver X receptors
b-amyloid
Huntington’s disease
huntingtin protein
magnetic resonance spectroscopy
type 2 diabetes
non-alcoholic fatty liver disease
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